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Abstract
Introduction: Infections produce severe respiratory muscle weakness, which contributes to the development of
respiratory failure. An effective, safe therapy to prevent respiratory muscle dysfunction in infected patients has not
been defined. This study examined the effect of eicosapentaenoic acid (EPA), an immunomodulator that can be
safely administered to patients, on diaphragm force generation following endotoxin administration.
Methods: Rats were administered the following (n = 5/group): (a) saline, (b) endotoxin, 12 mg/kg IP, (c) endotoxin +
EPA (1.0 g/kg/d), and (d) EPA alone. Diaphragms were removed and measurements made of the diaphragm force-
frequency curve, calpain activation, caspase activation, and protein carbonyl levels.
Results: Endotoxin elicited large reductions in diaphragm specific force generation (P < 0.001), and increased
diaphragm caspase activation (P < 0.01), calpain activation (P < 0.001) and protein carbonyl levels (P < 0.01). EPA
administration attenuated endotoxin-induced reductions in diaphragm specific force, with maximum specific force
levels of 27 ± 1, 14 ± 1, 23 ± 1, and 24 ± 1 N/cm
2, respectively, for control, endotoxin, endotoxin + EPA, and EPA
treated groups (P < 0.001). EPA did not prevent endotoxin induced caspase activation or protein carbonyl
formation but significantly reduced calpain activation (P < 0.02).
Conclusions: These data indicate that endotoxin-induced reductions in diaphragm specific force generation can
be partially prevented by administration of EPA, a nontoxic biopharmaceutical that can be safely given to patients.
We speculate that it may be possible to reduce infection-induced skeletal muscle weakness in critically ill patients
by administration of EPA.
Introduction
Infections produce severe respiratory muscle weakness,
which contributes to the development of respiratory fail-
ure [1,2]. An effective, safe therapy to prevent respira-
tory muscle dysfunction in infected patients has not
been defined. One approach to identifying a potential
therapeutic agent would be to evaluate the effects of
agents that can block cellular pathways known to be
pathophysiologically linked to the development of infec-
tion induced muscle dysfunction [3]. One such pathway
is the caspase proteolytic pathway, and infections have
been shown to activate the extrinsic caspase pathway,
increasing skeletal muscle caspase 3 activity [4]. In addi-
tion, infections stimulate intramuscular generation of
high levels of free radicals, activate the skeletal muscle
proteasomal proteolytic pathway, and trigger the skeletal
muscle calpain proteolytic system [5-7]. Each of these
pathways, moreover, is theoretically capable of interac-
ting with skeletal muscle contractile proteins and
thereby reducing force generation [8-10].
One pharmacologic agent, eicosapentaenoic acid
(EPA), inhibits caspase activation, reduces proteasomal
pathway activation, and is a free radical scavenger. Spec-
fically, EPA has been shown to inhibit activation of both
the intrinsic (that is, mitochondrial) and extrinsic (death
receptor related) caspase activation pathways [11]. This
agent has also been reported to be a weak free radical
scavenger and to have nonspecific antioxidant effects
[12]. More recently, this agent has been reported to act
as a proteasome inhibitor, blocking proteolysis and mus-
cle wasting in patients with pancreatic carcinoma [13],
reducing proteasomal activation in an animal model of
sepsis [14], and reducing the resting level of cytokines
[15]. Moreover, EPA is well tolerated and has been
safely administered to patients without reports of
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on these past reports, it is reasonable to postulate that it
may be rational to utilize EPA to prevent muscle weak-
ness in infected patients. No previous study, however,
has examined the effect of EPA on skeletal muscle force
generating capacity, and it is not known if this agent
can prevent skeletal muscle weakness in either patients
or animal models of infection.
The purpose of the present experiment, therefore, was
to test the hypothesis that administration of EPA would
attenuate the effects of endotoxin (LPS) induced sepsis
on diaphragm force generating capacity. Studies were
conducted in rats and comparison made of diaphragm
force generation, protein content, and muscle mass
between groups of control animals, animals treated with
endotoxin, animals given both endotoxin and EPA, and
animals given EPA alone. We also sought to determine
if EPA administration attenuates the activation of one or
more of the downstream mechanisms by which endo-
toxin administration alters skeletal muscle force genera-
tion. To do so, we measured indices of caspase 3
activation, free radical formation, and calpain activity for
diaphragm samples taken from the four animal groups
studied in this experiment.
Materials and methods
Protocol
Experiments were performed using rats 250 to 350 g in
weight. Approval for this work was granted by the Insti-
tutional Animal Care and Use Committee. Animals
were given food and water ad lib and housed in univer-
sity facilities. Saline (60 mg/kg/d) was administered sub-
cutaneously to maintain fluid volume status. Animals
were sedated with pentobarbital (50 mg/kg intraperito-
neally) before euthanasia.
Studies were performed on groups of rats (n = 5/
group) given: (a) saline, 0.3 ml IP and a 0.5 ml olive oil
gavage/d, (b) endotoxin, 12 mg/kg of E. coli lipopolysac-
charide administered in 0.3 ml saline, Sigma Chemicals,
St. Louis, MO, USA IP, and a 0.5 ml olive oil gavage/d,
(c) endotoxin and EPA (1.0 g/kg/d administered in a 0.5
ml olive oil gavage), and (d) saline, 0.3 ml IP, and EPA
(1.0 g/kg/d administered in a 0.5 ml olive oil gavage).
EPA was administered in this dosage and given in an
olive oil gavage based on previous work using this agent
[17,18]. Animals were killed at 48 hours because pre-
vious work in our laboratory found that diaphragm spe-
cific force levels fall to a nadir by that time after
endotoxin administration [19,20]. At the time of sacri-
fice, diaphragms were removed and the following were
measured: (a) diaphragm weight, (b) total diaphragm
protein levels, (c) the diaphragm force-frequency rela-
tionship, (d) caspase 3 activity using a fluorogenic assay,
(e) diaphragm carbonyl content, an index of free radical
generation, (f) calpain activity using a fluorogenic assay,
and (g) procalpain I and active calpain I levels using
Western blotting. No animals died before tissues could
be harvested.
Determination of diaphragm specific force generation
Diaphragm force generation was assessed as we have
previously reported [21]. In brief, after diaphragms were
excised and placed in a dissecting dish, muscle strips
were dissected from the left mid-costal portion. Strips
were then mounted vertically in water jacketed glass
organ baths containing Krebs-Henselheit solution (25°C,
curare 50 mg/l, pH 7.40, NaCl 135 mM, KCl 5 mM,
dextrose 11.1 mM, CaCl2 2.5 mM, MgSO4 1m M ,
NaHCO3 14.9 mM, NaHPO4 1 mM, insulin 50 units/L,
95% O2/5% CO2). One end of each strip was tied to the
base of the organ bath and the other end to a SI force
transducer (Scientific Instruments, Heidelberg, Ger-
many). Platinum mesh field electrodes were used to
deliver supramaximal currents using a biphasic constant
current amplifier driven by a Grass S48 stimulator
(Grass, West Warwick, RI, USA). After a 15 minute
equilibration period, muscle strip length was adjusted to
Lo,t h a ti s ,t h el e n g t ha tw h i c hs t r i pf o r c eg e n e r a t i o ni n
response to single stimuli was maximal. Strips were then
sequentially stimulated with trains of 1, 10, 20, 50, and
80 Hz. stimuli (train duration 800 msec, 30 sec between
adjacent trains) and force recorded with a Gould 2600
strip chart recorder (Gould, Cleveland, Ohio, USA).
A cross sectional area was calculated as muscle strip
weight divided by muscle density (1.06) and muscle
length [22]. Specific muscle force was calculated as raw
force divided by cross sectional area.
Assessment of diaphragm calpain and caspase 3 activity
For calpain and caspase activity assays, diaphragm samples
were first homogenized in a 1 g/10 ml ratio in assay buffer
(50 mM HEPES, 100 mM NHCl, 0.1% CHAPS, 10 mM
DTT, I mM EDTA, 10% glycerol, pH 7.4) using a polytron
while on ice. Samples were centrifuged at 10,000 G for
10 minutes at 4°C, the supernatant removed and assayed
for protein content. Diaphragm homogenates (100 micro-
grams of supernatant protein) were added to assay buffer
and either a calpain-specific fluorogenic substrate (Suc-
LLVY-AMC, that is, Succinyl-Leu-Leu-Val-Tyr-7-amido-
4-methyl-coumarin) or a caspase 3 specific substrate
(Ac-DEVD-AMC, that is, N-acetyl-Asp-Glu-Val-Asp-7-
amino-4-methylcoumarin). Duplicate determinations were
made for each sample using a mixture of diaphragm
homogenate, assay buffer, fluorogenic substrate and either
a highly specific calpain inhibitor (0.1 mg/ml calpain inhi-
bitor III, carbobenzoxy-valinyl-phenylalaninal) or a caspase
3 inhibitor (20 nM DEVD-CHO, that is, N-acetyl-Asp-
Glu-Val-Asp-aldehyde). Immediately after the addition of
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(7-Amino-4-methylcoumarin) was performed using a
Molecular Devices spectrofluorophotometer (Molecular
Devices, Silicon Valley, CA, USA) (excitation frequency of
360 nm and emission frequency of 460 nm). This mea-
surement was repeated after 0.5 hour of incubation at
30°C for caspase assays and after 0.5 hour of incubation at
25°C for calpain assays. AMC standards were used to cre-
ate a calibration curve and activity was quantified as
nmoles of AMC generated/min/mg of tissue homogenate.
The difference between AMC generation from incubation
of homogenates with Suc-LLVY-AMC in the presence and
absence of calpain inhibitor III was used as an index of
calpain activity; note that calpain inhibitor III inhibits cal-
pain activity but does not inhibit proteasomal activity.
Similarly, the difference between AMC generation from
incubation of homogenates with Ac-DEVD-AMC in the
presence and absence of DEVD-CHO was used as an
index of caspase 3 activity. Note that DEVD-CHO does
not inhibit calpain, caspase 8 or caspase 9 but specifically
inhibits caspase 3.
Western blots and oxyblot protein modification
determinations
SDS-PAGE protein gels were run for Western blot analy-
sis of specific proteins (that is, calpain I protein, Oxyblot
protein carbonyl sidegroup formation). The purpose of
assessing calpain I protein was to detect the presence of
the 78 kDa calpain I cleavage product. This cleavage pro-
duct is known to be formed autocatalytically when cal-
pain I is activated. Arguably, this is a superior means of
determining if calpain I is active in intact tissues than
many traditional indices. For example, some techniques
to assess calpain activation employ initial isolation of cal-
pain I, calpain II, and/or calpastatin from tissues and sub-
sequent assessment of calpain or calpastatin activity of
the isolated proteins (for example, zymography), but this
approach assesses the in vitro activity of these enzymes
or their inhibitor (calpastatin) and does not determine
the activity of these enzymes under in vivo conditions. In
contrast, the presence of the 78 kDa calpain I cleavage
product in diaphragm homogenates can only occur from
in vivo calpain I activation in the diaphragm.
The specifics for performing Oxyblot and calpain I
blots are as follows. Prior to SDS-PAGE gel analysis,
samples (10 μg/lane) used for Oxyblot determination
were prepared as per the manufacturer’s instructions
(Oxyblot Kit, Chemicon, Temecula, CA, USA). Nonder-
ived protein samples for calpain I determinations (100
μg/lane) were diluted with an equal volume of a loading
buffer (126 mM Tris-HCL, 20% glycerol, 4% SDS, 1.0%
2-mercaptoethanol, 0.005% bromphenyl blue, pH 6.8).
Samples were then loaded onto 12% Tris Glycine
polyacrylamide gels and proteins separated by electro-
phoresis (Novex Minicell II; Invitrogen, Carlsbad, Ca.
USA). Standard molecular weight markers were also
loaded onto gels to permit approximation of protein
band molecular weights. After electrophoresis, proteins
were transferred to polyvinylidene fluoride membranes
and incubated over night at 4°C with antibodies to tar-
geted proteins (anti-calpain I, Chemicon, and anti-DNP
antibody for Oxyblot determination, Chemicon). Mem-
branes were then incubated with horse radish peroxi-
dase (HRP) conjugated secondary antibodies and
antibody binding was detected using enhanced chemilu-
minescence (NEN Life Science Products, Boston,
MA, USA). Gel densitometry was performed using a
Microtek scanner (Carson, CA, USA) and UN-SCAN-IT
software (Silk Scientific, Orem, UT, USA). Since calpain
I cleavage is an index of in vivo calpain I activation, cal-
pain densitometry is reported as the ratio of cleaved
calpain I to intact calpain I protein levels. This normali-
zation procedure also corrects for lane to lane differ-
ences in protein loading; to further assess protein
loading, parallel gels were run probing for a-tubulin.
Statistics
ANOVA was used for comparison of parameters across
experimental groups. Tukeys test was used to determine
differences between individual groups following
ANOVA. A P-value of less than 0.05 was taken as indi-
cating statistical significance. Data are presented as
mean ± SEM (standard error of mean).
Results
Effects of endotoxin and EPA on the diaphragm force-
frequency relationship
Endotoxin (LPS) administration produced a large reduc-
tion in diaphragm specific force generation, that is, the
force generated per unit cross sectional area (Figure 1).
LPS induced reductions in diaphragm force generation
were evident for all stimulation frequencies tested (1 to
80 Hz), with maximum force reduced by 48% when
compared to values for control experiments (P < 0.001
for comparison of 80 Hz force for control and LPS trea-
ted groups). More importantly, EPA administration sub-
stantially attenuated this LPS induced reduction in
diaphragm force, with the specific force-frequency curve
for the LPS + EPA group lying above the curve for the
LPS treated group (P < 0.01 for comparison of specific
force between LPS and LPS + EPA treated groups at sti-
mulation frequencies 1, 20, 50, and 80 Hz). The EPA +
LPS group was similar to control levels for stimulation
frequencies 1 to 20 Hz but remained lower than control
levels for 50 and 80 Hz force measurements (P <0 . 0 5
for these latter comparisons).
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At 48 hours following endotoxin (LPS) administration,
diaphragm weight (mass) and protein content
remained at levels similar to those measured on dia-
phragms from control animals. Specifically, diaphragm
weight averaged 1.73 ± 0.05, 1.69 ± 0.04, 1.58 ± 0.09,
and 1.90 ± 0.10 g/initial body weight-g, respectively
for control, LPS, LPS + EPA and EPA treated groups
(NS). In addition, diaphragm protein levels were
similar across the four groups, averaging 0.36 ± 0.02,
0.32 ± 0.03, 0.31 ± 0.03, and 0.37 ± 0.02 g/initial body
weight-g, respectively, for control, LPS, LPS + EPA,
and EPA alone treated groups (NS).
Effects on activation of caspase 3, protein carbonyl
formation and calpain activation
Previous work indicates that LPS reduces diaphragm
specific force generation by several mechanisms, includ-
ing via the effects of diaphragm caspase activation, free
radical induced alterations in protein function and
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Figure 1 Diaphragm force-frequency curves. Force generation was significantly lower at stimulation frequencies from 1 to 80 Hz for
diaphragms from LPS treated animals (filled circles) than for control animals (open squares) (P < 0.001). Diaphragms from animals given both
EPA (eicosapentanoic acid) and LPS generated forces significantly higher than diaphragms from animals given LPS alone for stimulation
frequencies of 1, 20, 50 and 80 Hz (P < 0.01 for each comparison). Forces generated by the EPA+LPS group were similar to controls for 1, 10 and
20 Hz but were lower than controls for 50 and 80 Hz (P < 0.05). Force generation for muscles taken from animals given EPA alone was similar to
levels for control animals. * indicates a significant statistical difference between endotoxin and all other groups.
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sought to determine if EPA administration blocked acti-
vation of one or more of these LPS-induced processes.
We found that LPS administration induced an increase
in diaphragm caspase 3 activity, as judged by the ability
of diaphragm homogenates to cleave a caspase 3 specific
fluorogenic substrate (P < 0.01, Figure 2). Administra-
tion of EPA, however, had no effect on LPS-induced
diaphragm caspase 3 activation, which remained signifi-
cantly higher for the LPS + EPA group compared to
control (P < 0.01). We also found that LPS administra-
tion significantly increased diaphragm protein carbonyl
content (see Figure 3, P < 0.01 for carbonyl densitome-
try levels between control and LPS treated groups). EPA
administration also failed to attenuate protein carbonyl
formation, with protein carbonyl densitometry for the
LPS + EPA group similar to that of the LPS alone group
and higher (P < 0.05) than values for controls.
In contrast, EPA largely prevented LPS induced cal-
pain activation (Figures 4 and 5). In keeping with pre-
vious reports, we found that LPS significantly increased
diaphragm calpain activation as measured using a
fluorogenic substrate based assay (P <0 . 0 0 1 ,F i g u r e4 )
and by measuring diaphragm levels of cleaved calpain I
protein (that is, active, cleaved 78 kDa calpain I protein,
P < 0.01, Figure 5). EPA blocked both of these increases,
with calpain activity levels for the LPS + EPA group sig-
nificantly lower than levels for the LPS alone group
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Figure 2 Diaphragm caspase 3 activity. Diaphragm caspase 3 activity was significantly increased for samples taken from animals after LPS
treatment (filled bar) as compared to controls (open bar) (P < 0.01). EPA administration did not prevent this increase in diaphragm caspase 3
activity, with caspase 3 activity higher for the EPA plus LPS group (light grey bar) as compared to controls (P < 0.01). This parameter was similar
in control and the EPA alone group (dark grey bar) and the EPA alone group was different from the LPS alone group (P < 0.01). * indicates a
significant statistical difference compared to control and EPA alone groups.
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calpain I protein levels for the LPS + EPA group sub-
stantially lower than the level obtained for the LPS
alone group (P < 0.02, Figure 5).
Discussion
Respiratory muscle dysfunction in the intensive care unit
Severe respiratory muscle weakness is commonplace in
patients requiring intensive care. This was best demon-
s t r a t e db yt w or e c e n ts t u d i e st h a tu t i l i z e dm a g n e t i c
stimulation techniques to objectively and non-volition-
ally assess diaphragm pressure generating capacity in
critically ill patients requiring mechanical ventilation
[23,24]. Both studies found that these patients had sur-
prisingly severe diaphragm muscle weakness, with the
patients in this study generating transdiaphragmatic
pressures in response to magnetic twitch stimulation
that averaged only 25% of the levels seen in normal
healthy individuals. This severe respiratory muscle weak-
ness compromises the ability of critically ill patients to
Figure 3 Oxyblot determination. Diaphragm protein carbonyl content, as assessed by the oxyblot technique, is shown for representative
diaphragm samples in the top blots while group mean densitometry data is presented in the bottom graph. Protein carbonyl levels were
increased for diaphragm samples taken from animals after LPS treatment as compared to control animals (P < 0.01). EPA administration did not
reduce carbonyl levels significantly in LPS treated animals. Carbonyl levels for animals given EPA alone were similar to levels in saline treated
controls. * indicates a significant statistical difference compared to control and the EPA alone groups.
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support in patients with lung disease and increasing the
risk for recurrent respiratory failure once mechanical
ventilation is removed [25].
Research has identified several pathophysiological pro-
cesses that contribute to the development of respiratory
muscle weakness in critically ill patients [1,2,26,27]. One
important factor is infection, with several human studies
demonstrating that infections can induce severe reduc-
tions in respiratory muscle strength [1,2]. Studies utiliz-
ing animal models of infection have confirmed this
association, demonstrating the development of severe
diaphragm weakness following endotoxin injection [28],
after induction of pseudomonal pneumonia [29], follow-
ing cecal ligation-puncture induced peritonitis [30] and
after parasitic infections [31]. The mechanisms by which
infections induce respiratory muscle dysfunction remain
incompletely understood, but recent work has identified
several cellular pathways that may contribute to the
development of this problem. First, infections appear to
increase diaphragmatic levels of oxygen derived free
radical species (for example, peroxynitrite) and early
administration of scavengers/inhibitors of reactive oxy-
gen species have been shown to reduce the development
of diaphragm dysfunction in several models of infection
[32,33]. Second, work suggests that infections induce
caspase activation in striated muscles (cardiac muscle,
diaphragm, limb muscles) and that caspase mediated
contractile protein cleavage may underlie, at least in
part, some of the skeletal muscle and cardiac contractile
dysfunction seen with infections [19,34]. Third, infec-
tions increase activation of the proteasome and calpain
proteolytic enzyme systems which, in turn, are thought
to contribute to skeletal muscle protein loss and atrophy
during sustained infection [35-37].
Effects of EPA
Several studies have shown that chemical inhibitors of
several of the pathophysiological pathways identified in
the preceding paragraph can significantly reduce
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Figure 4 Diaphragm calpain activity. Diaphragm calpain activity was significantly increased for samples takenf r o ma n i m a l sa f t e rL P S
treatment (filled bar) as compared to controls (open bar) (P < 0.001). EPA administration reduced this increase in diaphragm calpain activity,
with calpain activity lower for the EPA plus LPS group (light grey bar) as compared to LPS treated animals (P < 0.02). Diaphragm calpain activity
for samples from animals given EPA alone (dark grey bar) was similar to levels for the control group. * indicates a significant statistical difference
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models of infection. Agents that have been found to be
effective in this manner include zVAD-fmk (a caspase 3
inhibitor), IEHD-fmk (a caspase 8 inhibitor), calpain
inhibitor III (a calpain inhibitor), and PEG-SOD (a
superoxide inhibitor) [32,34,38]. While all of these
agents are reasonably effective in preventing the devel-
opment of diaphragm weakness in animal models of
sepsis, none of these agents are FDA approved to treat
human disease, many have never been administered to
humans, and the risks and side effects of most of these
agents are virtually unknown.
In contrast, numerous studies have employed EPA in
animals and humans and to date there are no reports of
serious side effects. The current study suggests a poten-
tial new use for this agent and also identifies a pre-
viously unrecognized mechanism of action of the drug.
We found that this agent largely preserved diaphragm
strength following endotoxin administration. In compar-
ison to previous studies examining endotoxin induced
Figure 5 Calpain I protein levels for diaphragm samples. Western blots stained for calpain I protein, with top panels presenting blots for
representative samples and the bottom graph providing group mean densitometry data for cleaved calpain I/intact calpain I protein levels. Blots
were reprobed with alpha tubulin to verify equal loading of lanes. Levels of cleaved calpain I (78 kDa protein)/total calpain I were higher for
samples after LPS treatment (filled bars) than for samples from control animals (open bars), animals given both LPS and EPA (light grey bars) or
animals given EPA alone (dark grey bars)(P < 0.02). * indicates a significant statistical difference from the other groups.
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compare favorably to the beneficial effects produced by
caspase inhibitors, p38 inhibitors and very selective
potent calpain inhibitors (that is, calpain inhibitor III) in
reducing endotoxin induced diaphragm dysfunction
[28,32,34,39].
Another important finding of the current study is that
the mechanism by which EPA appeared to prevent dia-
phragm dysfunction appears to be unrelated to pre-
viously published reports. Our findings indicate that this
agent did not appear to inhibit caspase 3 activation,
since caspase 3 activity assay levels were unchanged
with this drug. While we cannot rule out an effect of
EPA to modify free radical generation in selective mus-
cle organelles (for example, lipid peroxidation of mem-
branes), our data indicate it failed to substantially
modify diaphragm protein carbonyl formation following
endotoxin administration. The fact that this agent failed
to inhibit caspase activation and failed to block protein
carbonyl formation in the diaphragm also indicates that
this agent did not act nonspecifically to downregulate
the inflammatory response to endotoxin.
On the other hand, EPA did inhibit diaphragm calpain
I activation, as evidenced by the fact this agent reduced
both formation of active cleaved calpain I protein and
reduced diaphragm calpain activity as gauged from a
fluorogenic activity assay. This is the first report, of
which we are aware, demonstrating that EPA has the
capacity to inhibit calpain in an animal model of disease.
There are two potential mechanisms by which calpain
may have had this effect. First, calpain I is a calcium
dependent enzyme whose activation is initiated by subtle
increases in intracellular calcium concentrations in the
vicinity of calpain molecules [38]. Once activated, this
enzyme autocatalytically cleaves itself (see Figure 5, for-
mation of a 78 kDa band in the diaphragm after endo-
toxin administration), with some data suggesting that
this cleavage product is substantially more active at low
calcium concentrations than the parent molecule [34].
Resting muscle calcium concentrations are known to
increase in sepsis, and it has been postulated that this
increase may be responsible for infection induced cal-
pain activation [40]. EPA has been previously shown to
incorporate into endoplasmic reticulum and sarcoplas-
mic reticulum membranes and thereby modulate cal-
cium release and reuptake by these structures [41]. It is
therefore theoretically possible that EPA may so alter
sarcoplasmic reticulum (SR) function that it blocks cyto-
solic calcium increases and calpain activation following
endotoxin administration. EPA has been reported to
alter the activation of several kinases and calpain activa-
tion in muscle is thought to be, at least in part, modu-
lated by kinase (that is, Extracellular Signal Regulated
Kinase (ERK)) induced phosphorylation [42]. It is
therefore also theoretically possible that EPA may have
induced its effect by altering kinase mediated calpain I
activation. Finally, one study has suggested that skeletal
muscle calpain activation in sepsis is secondary, at least
in part, to loss of activity of calpastatin, the endogenous
calpain inhibitor [43]. It is therefore also possible that
EPA administration may block calpastatin inactivation,
thereby reducing calpain activity and calpain autocataly-
tic cleavage.
Implications
As indicated earlier, EPA is thought to be a relatively
innocuous agent with few side effects. In fact, this drug
has been administered safely in studies of patients in
critical care units with no reported morbidity or mortal-
ity attributed to the drug [44]. The current study sug-
gests that EPA may be useful in critically ill patients to
reduce infection induced diaphragm weakness. More-
over, since it appears that this agent acts by inhibiting
calpain activation, it should also, theoretically, be effec-
tive in reducing diaphragm dysfunction in other situa-
tions in which calpain mediated diaphragm damage is
thought to be present. Specifically, calpain activation has
been implicated as the cause of mechanical ventilator
induced diaphragm dysfunction in rats [26], and also, as
a potential contributor to hyperglycemia induced dia-
phragm dysfunction (personal communication, LA Call-
ahan). Future studies will be needed, therefore, to
determine if EPA administration can be used therapeuti-
c a l l yi nt h ei n t e n s i v ec a r eu n i tt op r e v e n tr e s p i r a t o r y
muscle weakness in infected, mechanically ventilated,
and/or hyperglycemic patients. In addition, the protocol
employed in the present study used EPA as a prophylac-
tic agent, with initiation of administration of this drug
at the time of endotoxin injection. Additional work will
be needed to determine if this agent is also effective at
latter time points and if it can rescue muscle function
after an initial damaging insult.
Conclusions
These data indicate that endotoxin-induced reductions
in diaphragm specific force generation can be partially
prevented by administration of EPA, a nontoxic immu-
nomodulator that can be safely given to patients. We
speculate that it may be possible to reduce infection-
induced skeletal muscle weakness in critically ill patients
by administration of EPA.
Key messages
￿ Endotoxin-induced sepsis causes severe reductions
in diaphragm strength.
￿ Administration of Eicosapentanoic acid (EPA) par-
tially prevents endotoxin-induced diaphragm
weakness.
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ing diaphragm calpain activation.
￿ W es p e c u l a t et h a tE P Am a yb eu s e f u li np r e v e n t -
ing weakness in critically ill patients.
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HEPES: 4-(2-hydroxyethyl)-1-piperazine bethanesulfonic acid; HRP: horseradish
peroxidase; IEHD-fmk: Ile-Glu-Thr-Asp-fluoromethylketone; LPS:
lipopolysaccharide; NS: non significant; zVAD-fmk: carbobenzoxy-valyl-alanyl-
aspartyl-[O-methyl]-fluoro-methylketone; PEG-SOD: polyethylene glycol
superoxide dismutase; SDS: sodium dodecyl sulfate; SDS-PAGE: sodium
dodecyl sulfate polyacrylamide gel electrophoresis; Suc-LLVY-AMC: Succinyl-
Leu-Leu-Val-Tyr-7-amido-4-methyl-coumarin.
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